InvestorsHub Logo
Followers 1
Posts 347
Boards Moderated 0
Alias Born 12/09/2016

Re: None

Saturday, 03/11/2017 8:55:21 PM

Saturday, March 11, 2017 8:55:21 PM

Post# of 108192
I did not know adxs was receiving development and licensing fees from global bio pharma (GBP). It looks like on gbp website like the company was created just for adxs?

During the quarter ended January 31, 2017, the Company recorded revenue of $3,790,842. The Company recognized $3,540,842 of revenue from the collaboration agreement with Amgen related to amortization of the upfront fees received. In addition, $250,000 of revenue was due to the receipt of an annual exclusive license fee from GBP for the development and commercialization of Axalimogene filolisbac.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News